Capstar Special Purpose Acquisition Corp. (CPSR) to Combine with Gelesis in $964M Deal

Capstar Special Purpose Acquisition Corp. (CPSR) to Combine with Gelesis in $964M Deal

Capstar (NYSE:CPSR) has entered into a definitive agreement to combine with biotherapeutics firm Gelesis at an enterprise value of $964 million, or 5.6x its 2022E net sales. Boston-based Gelesis is advancing a series of therapies for weight management and chronic gut conditions with a consumer-facing approach. The combined company is expected to trade on the
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.